Long-term results of a hydroxyapatite-coated femoral component in total hip replacement: a 15- to 21-year follow-up study

J Bone Joint Surg Br. 2008 Jan;90(1):27-30. doi: 10.1302/0301-620X.90B1.19731.

Abstract

Between 1986 and 1991 we implanted 331 consecutive Furlong hydroxyapatite-coated femoral components of a total hip replacement in 291 patients. A cemented acetabular prosthesis was used in 217 hips and a hydroxyapatite-coated component in 114. We describe the long-term clinical and radiological survival of the femoral component at a mean follow-up of 17.5 years (15 to 21). Only two patients (0.68%) were lost to follow-up. With revision of the femoral component for any reason as the endpoint, the survival at a mean of 17 years was 97.4% (95% confidence interval 94.1 to 99.5), and with revision for aseptic loosening as the endpoint it was 100%. The survival at a maximum of 21 years with revision of the femoral component for any reason as the endpoint was 97.4% (95% confidence interval 81.0 or 99.5). These results compare favourably with the best long-term results of cemented or uncemented femoral components used in total hip replacement.

MeSH terms

  • Acetabulum / surgery*
  • Adult
  • Aged
  • Aged, 80 and over
  • Arthroplasty, Replacement, Hip / methods*
  • Biocompatible Materials / therapeutic use*
  • Cementation
  • Durapatite / therapeutic use*
  • England
  • Follow-Up Studies
  • Hip Joint / surgery*
  • Hip Prosthesis*
  • Humans
  • Middle Aged
  • Prospective Studies
  • Prosthesis Design
  • Prosthesis Failure
  • Treatment Outcome

Substances

  • Biocompatible Materials
  • Durapatite